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ABSTRACT
Objectives: Existing instruments that measure the impact of cancer-
related fatigue on health-related quality of life do not usually incorpo-
rate the attitudes, beliefs and perspectives of patients. This study aimed
to develop an instrument to measure the impact of cancer-related fatigue
on the health-related quality of life of cancer patients.
Methods: Items were generated from a literature review, focus groups of
cancer patients and meetings with oncologists. Potential items were
administered to cancer patients to facilitate item reduction, which was
based on clinimetric and psychometric analyses and qualitative criteria. A
preliminary assessment of feasibility, reliability and validity of the retained
items was performed.
Results: An initial pool of 75 items was administered to 238 cancer
patients. Fifty items were eliminated after statistical analysis and 13 in
response to expert opinion, resulting in a provisional instrument with 12
items in 3 dimensions. These displayed acceptable internal consistency
(Cronbach’s alpha, 0.78–0.92) and their overall score was associated with
fatigue intensity, extent of disease, intention of treatment and need of
caregivers.
Conclusion: The newly developed questionnaire, which measures the
impact of cancer-related fatigue on oncology patients, has shown satisfac-
tory feasibility, reliability and validity.
Keywords: cancer, development, fatigue, quality of life, questionnaire.
Introduction
Fatigue is a frequently reported complaint in cancer patients and
survivors, and has been deﬁned as “a persistent, subjective sense
of tiredness related to cancer that interferes with usual function-
ing” [1]. A recent survey found that 76% of patients experience
fatigue for at least a few days each month during chemotherapy,
30% experience fatigue on a daily basis, 91% of those who
experience fatigue report that it prevents a “normal” life and
88% report that fatigue causes changes in their daily routine [2].
The magnitude of their cancer-related fatigue is perceived to be
greater than the tiredness sometimes felt by healthy individuals
and is not relieved by rest [3]. One study reported that fatigue has
a greater impact on the quality of life than pain or depression,
symptoms also frequent in cancer patients [4].
Several questionnaires are available that measure the inten-
sity, frequency and duration of fatigue, whereas others aim to
measure the impact of fatigue on a patient’s quality of life [5–10].
Fewer instruments are available that measure the patient’s beliefs
and attitudes about cancer-related fatigue, even though this type
of information may be useful in patient management [11]. The
use of patient-reported measures in the daily practice of oncology
has also been shown to be helpful in improving patient–physician
communication in daily clinical oncology practice [12,13],
although this is a relatively new study environment in which
there are many matters of interest, pending solutions, within
clinical practice and research [14].
Up to now, none of the existing instruments that measure the
impact of cancer-related fatigue has been developed with
Spanish-speaking patients, which may be important because the
usual practice of adapting existing measures for use in other
languages does not guarantee the inclusion of issues relevant to
patients in the target population [15,16]. Similarly, many existing
instruments that measure cancer-related fatigue have been devel-
oped for use in clinical research rather than in clinical practice,
and their length, content, scoring system or psychometric prop-
erties may limit their applicability to routine use with individual
patients.
The aim of this study was to develop an instrument to
measure patient perceptions of the cancer-related fatigue and its
treatment that would be suitable for use in clinical practice.
Material and Methods
The three main phases of the project consisted of 1) item gen-
eration; 2) item reduction and testing of the structural validity
and internal consistency of the instrument with the data collected
in the ﬁrst ﬁeld study using a sample of target patients; and 3) the
assessment of the psychometric properties of the ﬁnal version,
with the data collected from a second ﬁeld study, with another
sample of target patients. Because of the amount of information
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collected, this article reports the main results of the ﬁrst two steps
of the overall project. An overview of the procedures applied is
shown in Figure 1.
Item Generation
The content of the questionnaire was developed from 2004 to
2005 from a literature review, focus groups and expert opinions
from oncologists and experts in the development of patient-
reported outcomes (PRO) measures. The literature review was
performed using several electronic sources including the US
National Cancer Institute Web site and the MEDLINE database
(1966–2004), with the keywords: fatigue, asthenia, question-
naire, scale, instrument, oncology, cancer, assessment, measure,
measurement, expectations, relief, satisfaction, perceptions and
worries. The articles located were searched manually for further
relevant articles. A citation was selected for review when it
referred to either the use or development of PRO instruments
that measured the impact of cancer-related fatigue or its treat-
ment, or patients’ expectations, beliefs and concerns about
cancer-related fatigue. For each questionnaire located, the fol-
lowing data were reviewed: instrument’s name, target popula-
tion, item number, dimensions, response scale and time frame.
The review of instruments was mainly intended to identify the
usual questionnaire content at the domain level, and to provide
information on aspects that could be useful for constructing the
ﬁnal version of our questionnaire, such as time frames, response
options and instructions.
The initial consultation with experts took place in two meet-
ings, one in Barcelona and one in Madrid. We used a structured
brainstorming technique to establish the experts’ views on the
potential content, usefulness and characteristics (such as length,
mode of administration and scoring) of the new questionnaire.
Experts attending the meetings included clinical specialists and
experts in the development and testing of PRO measures. The
main areas discussed were the ways patients experienced and
dealt with cancer-related fatigue, their main concerns relating
to the symptoms, the possible uses of the questionnaire from
the clinician’s point of view and general questionnaire character-
istics that would make it practicable for use in standard clinical
practice.
Two focus groups were conducted of patients who had expe-
rienced cancer-related fatigue at any time during the course of
their disease. A convenience sample was used with a relatively
small number of participants because the concept to be measured
was considered to be relatively restricted [17]. Participants were
chosen to ensure a broad range of clinical and socio-demographic
characteristics, and patients in both focus groups gave their
consent to participation. Both sessions were led by a moderator
(a member of the research team), assisted by a script developed
speciﬁcally for this purpose, which included aspects identiﬁed as
relevant in the literature review and during the meetings with the
clinical experts. The meetings were recorded on audiocassettes
and transcribed for subsequent analysis.
Transcripts from the focus groups were analysed using content
analysis by two of the study team members. The results of this
content analysis were used to develop an initial list of possible
items for inclusion in the questionnaire. The words and phrasing
used by focus group members were retained wherever possible.
The initial list of items was reviewed in a third meeting with
oncologists and experts in the development of PRO measures.
Items considered unsuitable for inclusion in the questionnaire
because of clinical irrelevance, redundancy of item content,
ambiguous content, or lack of face validity were omitted. An
agreement was reached by using “the last two weeks” as the time
frame for the items. This led to the creation of an item pool for
quantitative item reduction.
Item Reduction
Study design and participants. Items considered as candidates
for inclusion in the ﬁnal version of the questionnaire were admin-
istered to oncology patients with cancer-related fatigue in an
observational, cross-sectional, multicenter study performed
between January and April 2005 in the oncology or palliative
Literature review Focus groups Expert metaplans
Item reduction fieldwork 
(n = 238 patients)
Definitive 12-item 
version obtained
Initial item pool: 75 items
Statistical analysis and 
expert opinion for item 
reduction
Preliminary psychometric 
properties tested
Figure 1 Overview of study procedures. This
ﬁgure helps to have a general view of the main end
points achieved along the project, since the initial
design of item content until the obtainment of
the prevalidated 12-item version of the perform
questionnaire.
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care departments of 25 Spanish hospitals. Each center included
consecutive patients more than 18 years of age, with a diagnosis
of cancer (any site and period of disease duration, as long as they
were capable of completing the study questionnaires) and self-
rated cancer-related fatigue of 30 mm on a 100 mm visual
analogue scale (VAS) at the time of the study visit [18]. All
patients provided their informed consent to participation in the
study. The study was conducted according to the Declaration of
Helsinki.
Data were collected on the patient’s sex, age, level of educa-
tion and level of family care required. The clinical characteristics
recorded included the primary tumor type, extent of the disease,
time since diagnosis, Karnofsky or Eastern Cooperative Oncol-
ogy Group score or both on inclusion, intensity of cancer-related
fatigue measured on a 100 mm horizontal VAS, type of cancer
treatment and presence of associated symptoms or comorbidities.
Information on the mode of administration of the questionnaire
(interview or self-administration) was also collected.
All patients included in this phase of the study were asked how
frequently they experienced the situation presented in each of the
items and whether the item was important to them. For example,
the patient might be asked both how often he or she “had been
tired all day long” and how important this feeling was. Patients
rated the frequency and importance of items on 5-point scales
ranging from “never” to “always” and “not at all important” to
“very important.” Given that the patients responding to the items
in the item pool would be experiencing cancer-related fatigue, the
order of administration of the items was varied to ensure that
responses were obtained for all items.
Statistical analysis. Item reduction involved a series of steps: 1)
missing responses were analysed and items with >20% of
responses missing were excluded; 2) the response distribution
was analysed and items for which >50% of respondents checked
the same response category were excluded; 3) the frequency and
importance scores were analysed for each item. In this part of the
item reduction process, the product of the frequency and impor-
tance scores (the “impact” score) was obtained for each item and
then ranked according to this product, so that only the items that
were reported most frequently or were important to patients
were retained for further analysis; 4) exploratory factor analysis
using principal component analysis with varimax rotation was
used to explore the questionnaire structure and item loadings and
to identify factors with Eigen values of >1; 5) the relationships
between all items and their posited scales were analysed by the
calculation of corrected item–scale correlations and the analysis
of the impact on Cronbach’s alpha values when individual items
were deleted. Items with an item–scale correlation of 0.20 and
items that reduced the Cronbach’s alpha value of their scale were
excluded; and 6) the results of Rasch analysis, a form of item
response theory analysis [19] were used to support a ﬁnal round
of item elimination at a meeting of the study team.
Using the data collected in the item reduction study and with
the aim to explore the potential suitability of using the measure
in clinical practice, a preliminary validation of the retained items
was performed. In accordance with the cross-sectional design of
the study, the following analyses were done. An exploratory
factor analysis, using principal component analysis without rota-
tion, was carried out to explore the structure and item loadings,
and to identify the factors with Eigen values of >1. After the
recommendations set out in the literature [20,21], the overall
score for the ﬁnal version of the questionnaire was obtained by
adding the scores from all the items, and the score for each
dimension was obtained by adding the scores for the items in that
dimension. For individual patients included in the study, scores
for a given dimension was not calculated when the dimension
had any item missing. The ﬁnal score for a scale was not calcu-
lated when the dimension score could not be obtained. Feasibility
was assessed using the following indicators: completion rate
(percentage of respondents with no missing data) and missing
patient answers per item. The distribution of the overall and
dimension scores was described by calculating score range and
ﬂoor/ceiling effects (the proportion of patients with the worst
and the best possible score, respectively). Reliability for the
overall score and dimension score was assessed in terms of inter-
nal consistency using Cronbach’s alpha.
Known groups’ validity was tested by determining whether
the instrument was able to discriminate between patient groups
likely to differ in patient perceptions of the cancer-related fatigue:
cancer-related fatigue intensity, the extension (metastasis, loco
regional or local) of the disease, whether patients were still
having cancer treatment or in a follow-up phase, the intention
(curative, adjuvant, palliative) of the treatment and having a
caregiver for daily life were the tested independent variables.
Results
Item Generation
The literature review identiﬁed 35 citations that were considered
potentially relevant to the study. A review of the corresponding
documents identiﬁed 30 instruments (27 PRO questionnaires and
3 epidemiological survey instruments) that had been developed
to measure patient-reported aspects of cancer-related fatigue.
The questionnaires ranged from a single item to 40 items, and the
number of dimensions ranged from 1 to 7. Almost all the instru-
ments identiﬁed focused on aspects such as the intensity, fre-
quency and duration of fatigue, although some also measured
one or more of the following: quality of life, distress, psychologi-
cal impact and impact on motivation or activity and barriers to
patient–physician communication.
Nine oncologists and two experts in the development of PRO
measures attended the two meta-plan sessions to generate the
initial ideas for the development of the questionnaire. Asked to
consider the three main issues addressed in the meta-plan sessions
and the way patients cope with and experience cancer-related
fatigue, the participants mentioned the following as the most
relevant questions for patients: access to and the need for infor-
mation about cancer-related fatigue, the impact of cancer-related
fatigue on a patient’s quality of life, the search for alternative
therapies, fatigue as a symptom of worsening underlying illness
(cancer) and patient–doctor communication. When asked to con-
sider how they thought the questionnaire might be useful to them
in clinical practice and the characteristics that it should have, the
participants thought that the questionnaire should be useful in
both clinical research and practice, particularly for patient follow-
up, and that it might help improve the doctor–patient communi-
cation. The participants thought that the new instrument should
be easy to score and use, and that it should ﬁt onto one page and
be visually attractive. Most thought it should contain no more
than 10–12 itemswith a time frame spanning the “last twoweeks”
and that administration should be “ﬂexible,” i.e., suitable for both
self- and interview administration.
Most participants in the focus groups were patients with
breast cancer, although some patients had other types of cancer,
such as head cancer, neck cancer or lung cancer. All the patients
included were experiencing cancer-related fatigue at the time of
the focus groups or had experienced the symptom in the recent
past. The themes that emerged from the focus groups included
the following. It is important to distinguish between fatigue
resulting from the disease itself, fatigue resulting from treatment
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and fatigue associated with the psychological aspects of dealing
with the cancer (motivation to keep going despite the cancer).
The questionnaire should also document the way in which
patients experience the disease, particularly the fact that cancer-
related fatigue makes patients too tired to do things even when
they want to. Patients noted that family, friends and colleagues
could not really grasp their situation, and that in addition to the
considerable impact on functioning and daily activities, the psy-
chological and cognitive aspects related to fatigue were also
important. Patients would like their families, friends and col-
leagues, as well as medical staff, to have greater understanding of
their situation. They would also like more information on their
fatigue and how to deal with it.
Content analysis of the focus group transcripts, together with
input from the literature review and the meta-plans, led to the
development of an initial pool of 75 items. The items included
were grouped according to their meaning within the following
areas of interest: mental attitude (7 items), social and family life
(15 items), psychological impact (12 items), physical functioning
(12 items), daily life activities (12 items) and beliefs and attitudes
(17 items). To minimize the risk of producing a bias in the item
selection due to the physical location within the pool (e.g., com-
petitive disadvantage of the items at the end of the pool accumu-
lating more missing results or greater inconsistency in their
responses), the order of presentation of the areas of interest
mentioned previously by which the items were grouped differed
between the patients, in the way that all the studied patients
responded to the same content but with a different order of
appearance.
Item Reduction
The initial pool of 75 items was administered to 238 cancer
patients. The sample characteristics are shown in Table 1. The
mean age of the patient sample was 57 years (standard deviation
11.7) and 56% were female. The most frequent type of cancer
was breast cancer (30%), followed by lung cancer (18.1%);
30.3% of the patients had been diagnosed less than 6 months
before, but 64% of patients had metastasis. Sixty-three per-
cent of the patients presented a moderate fatigue level and the
rest a severe one. Most (62.6%) of the sample were receiving
palliative care, 18.5% were receiving adjuvant treatment and
10.1% curative treatment. Ninety-ﬁve percent of the sample
responded to at least 85% of the items.
Sixty-three of the initial 75 items included in the item reduc-
tion phase were eliminated. The reasons for their elimination and
the number of items eliminated at each stage of the item reduc-
tion process are shown in Figure 2. The greatest number of items
(n = 35) was eliminated in the ﬁrst stage of the item reduction
process based on their “impact” scores; the 40 items with the
highest “impact” scores were retained (see Table 2). Fifteen items
were eliminated because of low “item–total correlations” psy-
chometric parameter (0.20) in a three-step process: ﬁve items
were removed initially, another two items were removed after
factor analysis because they correlated only weakly with the
dimensions identiﬁed by factor analysis and a further ﬁve items
were removed after factor analysis because they correlated only
weakly with the new, reduced version of the overall scale. In the
ﬁnal stage of item reduction, 13 items were eliminated either
because they correlated highly with each other or because Rasch
analysis indicated the existence of redundancy in terms of item
difﬁculty. The decision about which items to retain when redun-
dancy or high correlations occurred was based on the relative
clinical relevance of the items and, in at least one case, on the
potential inappropriateness of the language used (Estoy hecho
polvo—I have felt “shattered”).
An additional factorial analysis was done on the 12 retained
items (see Table 3) that showed a unique factor that explained
the 53% variance. Item loading values ranged from 0.669 to
0.806 with the exception of two items with loading values of
0.491 and 0.583. The 12 items were grouped by domains on the
basis of the investigators’ experience. The ﬁnal instrument for
preliminary validation consisted of 12 items distributed in three
dimensions: physical function (items 1–4), activities of daily
living (items 5–8) and beliefs or attitudes (items 9–12).
Preliminary Validation
Table 4 shows the score distributions, ﬂoor/ceiling effects,
completion rate and internal consistency for the 12 items
retained. 22.7% of the sample had at least one item missing of
the 12 retained. Floor/ceiling effects were negligible (<5%) in all
dimensions and for the overall score. The highest ﬂoor/ceiling
effect was seen in the “Activities of daily living” dimension,
which had a ceiling effect of 3.4%. Cronbach’s alpha values were
more than 0.70 for the overall score and for all dimensions.
Table 5 shows the results of testing the known groups’
validity of the 12-item scale. Patients with a higher level of
Table 1 Demographics and disease characteristics of patients involved
in quantitative item reduction
All patients (N = 238)
Women, n (%) 133 (56)
Age (years), mean (SD) 57.2 (11.7)
Educational level (%)
No formal education 39 (16.5)
Primary education 82 (34.7)
Secondary education 61 (25.8)
University, or similar 54 (22.9)
Time from primary diagnosis (%)
<6 months 72 (30.3)
6 to 12 months 29 (12.2)
12 to 24 months 39 (16.4)
>24 months 78 (32.8)
Primary tumor type, n (%)
Breast 73 (30.8)
Lung 43 (18.1)
Gastrointestinal 42 (17.7)
Ovarian 12 (5)
Prostate 10 (4.2)
Esophageal 10 (4.2)
Other 48 (20.2)
Extent of disease, n (%)
Metastasis 154 (64.9)
Loco regional 40 (16.8)
Local 43 (18.1)
Type of cancer treatment, n (%)
Chemotherapy 187 (78.6)
Monoclonal antibodies 13 (5.5)
Hormone therapy 13 (5.5)
Radiotherapy 21 (8.8)
No treatment 14 (5.8)
Other 78 (32.8)
Principal symptoms, n (%)
Anemia 110 (46.2)
Pain 82 (34.5)
Anxiety or depression 81 (34)
Sleep complaints 41 (17.2)
Malnutrition 29 (12.2)
VAS fatigue level on inclusion, n (%)*
Moderate (30–60 mm) 150 (63)
Severe (>60 mm) 87 (36.6)
Karnofsky score on inclusion, mean (SD) 72.3 (20.2)
*Fatigue was measured on a 100 mm horizontalVAS. Patients rating between 0 and 30 were
not included in the study according to the inclusion criteria of the study. Patients in the study
were stratiﬁed as having a moderate or severe level of fatigue based on previous recom-
mendations [18].
SD, standard deviation;VAS, visual analogue scale.
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cancer-related fatigue had statistically signiﬁcant (P-value <
0.001) worse (lower) scores than did patients with a moderate
level of cancer-related fatigue, both in overall score and dimen-
sion scores (dimension activities of daily living P-value < 0.05).
The difference with respect to the overall scoring between
patients with moderate fatigue and those with severe fatigue was
>6 points on a scale with a range of 48 points, which represents
a difference in scores of >10%. Clinical variables, such as extent
of disease or treatment, also showed associations with the
scoring on the 12-item scale. In particular, the patients with very
localized cancer scored better (P-value < 0.05) in the overall
scoring than did those patients with more extensive disease or
metastasized disease, which was conﬁrmed in the beliefs and
attitudes dimension and showed up as a not statistically signiﬁ-
cant tendency in the physical limitations dimension. The patients
not undergoing any kind of treatment scored much better (45.29)
in the overall scoring than those patients undergoing some kind
of treatment (36.36) (P-value < 0.01), which could also be con-
ﬁrmed in the physical limitations dimension (P-value < 0.05).
Consistent with the aforementioned, the patients undergoing
curative treatment scored almost 7 points worse (lower) in the
overall scoring than did the patients undergoing adjuvant treat-
ment, perhaps because of the aggressiveness of the curative treat-
ment, which represents a difference of almost 15% between
extreme groups. This could also be conﬁrmed in the beliefs and
attitudes dimension. Last, the 12 items retained discriminated
between the patients who needed a caregiver and those who
didn’t, both in the overall scoring (P-value = 0.001) and in all the
scale dimensions (P-value = 0.016–0.006).
Discussion
To the best of our knowledge, ours is the ﬁrst study to create an
instrument that measures cancer-related fatigue taking into
account Spanish-speaking patient perspectives and that therefore
may have speciﬁc cultural and linguistic afﬁnities. Often, tools
are originally developed in English-speaking countries and later
on are translated and used in other non-English-speaking coun-
tries. On the contrary, the initial development of the present
measure was done with Spanish subjects (in Spain). Because the
difference between the Castilian Spanish spoken in Spain and
that spoken in Latin America or even the United States are
relatively small, the tool can be adapted for use in different
Spanish-speaking cultural contexts, providing that a suitable cul-
tural adaptation methodology is followed [15].
On the other hand, few, if any, of the existing instruments
include items that measured both the intensity of fatigue and its
impact on daily activities, as well as patient attitudes and beliefs
toward cancer-related fatigue. We considered all these aspects to
be important for inclusion in a measure intended primarily for
use in clinical practice, because the evaluation of these aspects
could help to facilitate better understanding about what aspects
are relevant for the oncological patient, but which are ignored or
unknown to the physician, thereby improving physician–patient
communication regarding cancer-related fatigue [22]. Further-
more, a number of the existing measures are not short enough for
use in clinical practice.
The strengths of our study include the use of a range of
sources to generate items for inclusion in the initial item pool,
and the explicit incorporation of the views of the potential users
of the questionnaire (oncologists) from the start of the develop-
ment process. We considered it important to incorporate the
views of practicing clinicians at various stages in the development
process, particularly because the instrument is intended primarily
for use in clinical practice. At the same time, incorporating
patient views in both the item generation and item reduction
stages helped to ensure the validity of the questionnaire’s
content. The use of a clinimetric analysis also ensured that the
most frequently occurring and/or most relevant items were
included in the questionnaire, although there is no consensus
with respect to which of the item reduction method processes is
the most suitable [23]. The ﬁnal version of the instrument con-
tains 12 items, which clinicians participating in the development
process felt was a suitable number for use in clinical practice.
This measure has been developed with the belief of converting it
No item removed because of missing responses 
5 items removed because of low item–total correlation 
2 items removed after factor analysis 
Initial pool of 75 items 
No item removed because of response distribution 
35 items removed because of low ranking 
Further 8 items removed because of low item–total correlation 
75 items 
75 items 
40 items 
35 items 
33 items 
25 items 
13 items removed on the basis of clinical opinion and Rasch analysis 12 items 
Figure 2 Items eliminated at different stages of
the item reduction process. This ﬁgure helps to
understand the criteria used for deleting items, and
how we arrive from the initial pool of 75 until the
ﬁnal 12-item version of the perform questionnaire.
At the same time, it shows the relevance of the
criteria used.
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into a real tool for the physicians who normally manage onco-
logical patients. For this reason, for example, two other aspects
considered relevant by clinicians and that were borne in mind
during the development of the measure were that the question-
naire should ﬁt onto one page and that it should be easy to use
and score. The factorial analysis done on the 12 retained items
identiﬁed a unique factor, whose items were dimensionally
grouped with regard to clinical criteria and the content of the
retained items. In particular, the questionnaire provides three-
dimension scores and an overall score, all of which are obtained
by simply summing the scores of individual items in the different
dimensions to produce a score ranging from 4 to 20 for the
individual dimensions and from 12 to 60 for the overall score,
with higher scores representing better quality of life. Although
the use of transformations and standardized scores in this type of
questionnaire may help in the interpretation of the scores, they
also make such scales difﬁcult for clinicians or other health-care
staff to use in daily practice [24].
The results of the preliminary analysis on the psychometric
properties of the new measure provide satisfactory evidence with
respect to the feasibility, reliability and validity of the tool. On
one hand, almost none of the patients obtained the worst or the
best possible overall score and dimension score, which suggests
that the questionnaire satisfactorily covers the perceptions of
cancer-related fatigue presented by the target population under
study. It can also be taken as an indication of whether a measure
will, at least theoretically, be capable of reﬂecting changes for
better or worse, within acceptable limits in all dimensions,
with fewer than 15% of patients having either the maximum or
the minimum score in any of the dimensions or the overall score
[25]. On the other hand, the completion rate, understood as the
rate of patients without missing responses in any of the 12
retained items, is quite satisfactory: that is to say, our study
purported to administer a pool of 75 items (each of one being
assessed in terms of frequency and importance) to a group of
patients with cancer-related fatigue, and to selected only a small
group of these items. It was estimated that the quantity of infor-
mation lost during the item pool administration would be high.
But, “only” 22% of the sample left 1 or more of the 12 retained
items unanswered. These results indirectly support the accept-
ability of the content of a questionnaire of this kind within a
study population.
On the other hand, the Cronbach’s alpha coefﬁcients
obtained were satisfactory. The Cronbach’s alpha values for all
the dimensions and for the overall score exceeded the suggested
minimum of 0.70 for use at the group level [21,26]. The overall
Table 2 Highest scoring items of the original 75 items (N = 238)
Mean (SD)
frequency
Mean (SD)
importance
Mean (SD)
impact score*
I have felt that I can count on my family for what I need. 1.22 (0.635) 1.23 (0.554) 1.58 (1.48)
I have noticed that my family is close to me. 1.29 (0.660) 1.25 (0.522) 1.72 (1.58)
I have been able to speak about my tiredness with relatives and friends who understand me. 1.85 (1.071) 1.88 (0.969) 3.82 (3.77)
In general, I believe that I speak sufﬁciently to the doctor about my tiredness. 2.05 (0.891) 1.96 (0.874) 4.24 (2.99)
My willingness to do things has helped me, in spite of the tiredness I feel. 2.10 (1.04) 1.86 (0.94) 4.27 (3.58)
In general, I believe that my tiredness is something unavoidable in my illness. 1.88 (1.03) 2.09 (1.12) 4.31 (4.04)
In general, I believe that my tiredness is associated with the treatment. 1.92 (0.97) 2.15 (1.05) 4.61 (4.00)
In general, I believe that I cope better with my tiredness. 2.63 (1.13) 2.02 (0.96) 5.39 (3.60)
My tiredness (due to my illness or its treatment) has been very different to “normal” tiredness.† 2.05 (1.24) 2.31 (1.16) 5.50 (5.40)
In general, I believe that my tiredness is associated with the illness. 2.34 (1.12) 2.14 (1.02) 5.51 (4.58)
In general, I believe my tiredness has made my life worse.† 2.34 (1.22) 2.11 (1.13) 5.75 (5.55)
I have not been able to walk quickly due to my tiredness. 2.46 (1.31) 2.14 (1.12) 5.95 (5.66)
I feel my tiredness has prevented me from living a normal life.† 2.65 (1.29) 2.09 (1.11) 6.41 (5.84)
After the medication sessions, I have been very tired and have not been able to do practically anything. 2.65 (1.26) 2.33 (1.17) 6.78 (5.44)
In general, I believe that I speak sufﬁciently to my nurse about my tiredness. 2.53 (1.11) 2.45 (1.14) 6.94 (5.56)
I have been very slow in performing my usual activities.† 2.55 (1.20) 2.42 (1.19) 6.94 (5.87)
I have had to sit down in situations where before I could do them standing up. 2.65 (1.16) 2.35 (1.13) 6.99 (5.82)
When I was tired, I had to interrupt what I was doing and rest to be able to continue.† 2.74 (1.21) 2.36 (1.10) 7.05 (5.41)
In general, I believe I need more information about my tiredness. 2.72 (1.23) 2.37 (1.16) 7.17 (5.70)
I have stopped doing things I liked doing because of my tiredness.† 2.98 (1.27) 2.23 (1.16) 7.32 (6.04)
Despite my tiredness, I have gone about my daily activities without problems. 3.14 (1.30) 2.31 (1.12) 7.36 (5.20)
My tiredness has concerned me. 2.71 (1.29) 2.36 (1.25) 7.48 (6.69)
Sometimes I have been more tired and at other times less tired throughout the day. 2.64 (0.93) 2.71 (1.02) 7.55 (4.46)
Going out with people/friends has helped me to forget about my tiredness. 3.03 (1.36) 2.29 (1.18) 7.63 (6.18)
I have felt shattered. 2.91 (1.27) 2.35 (1.18) 7.75 (6.36)
Going about my daily activities has been good for my tiredness. 3.17 (1.30) 2.39 (1.19) 8.01 (5.97)
The slightest effort makes me very tired.† 2.90 (1.38) 2.44 (1.27) 8.07 (7.03)
I have felt that my body does not respond, as if it was not mine. 3.08 (1.21) 2.36 (1.17) 8.14 (6.26)
I have been tired the whole day long.† 2.99 (1.22) 2.58 (1.18) 8.40 (6.16)
I have needed to have an afternoon nap. 2.59 (1.40) 2.86 (1.31) 8.43 (7.07)
I have stayed at home and have not gone out because of my tiredness. 3.08 (1.28) 2.53 (1.28) 8.54 (6.78)
I have needed help with tasks around the house because of my tiredness.† 3.09 (1.40) 2.49 (1.31) 8.57 (6.98)
I have felt too weak, because of my illness, to go on ﬁghting, to go ahead, because of my tiredness. 3.39 (1.27) 2.34 (1.18) 8.58 (6.31)
Sometimes I have short spells of tiredness and others longer. 2.93 (1.04) 2.79 (1.08) 8.61 (5.28)
In general, I believe that receiving so much attention from my family does not help me to overcome
my tiredness.
3.51 (1.34) 2.43 (1.21) 8.71 (6.04)
I have tried to do a little exercise (e.g., walking) but it is not good for my tiredness. 3.29 (1.25) 2.45 (1.15) 8.75 (6.25)
My tiredness has prevented me from doing daily tasks, for example, cooking or going shopping. 3.13 (1.34) 2.54 (1.30) 8.78 (6.93)
I have felt that I am going downhill because of my tiredness.† 3.55 (1.20) 2.31 (1.23) 8.83 (6.51)
I have spent the whole day sitting down because of my tiredness.† 3.27 (1.29) 2.49 (1.21) 8.85 (6.60)
I have felt bad about feeling tired at work.† 3.11 (1.44) 2.51 (1.36) 9.02 (7.63)
*Impact score = frequency ¥ importance.
†Item included in the ﬁnal version.
SD, standard deviation.
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score exceeded 0.90, which has been suggested to be the thresh-
old for a questionnaire of this type when used at the individual
level [25]. This is particularly important given that the aim of the
study was to produce a questionnaire that can be used to assess
and monitor individual patients in clinical practice. We note,
however, that the values we report were obtained within the
context of the item reduction study, i.e., from patients who
answered 75 items twice. These values may improve when
patients complete the ﬁnal version of the questionnaire and are
required to respond to each of the 12 items only once.
Moreover, the validity analysis of known groups showed that
the new tool’s scores behave coherently within the expectable,
with regard to the compared and deﬁned groups. In particular,
patients suffering from greater fatigue intensity, patients with
extended disease, patients having curative treatment and patients
with a caregiver presented a worse overall score than those
patients with less fatigue intensity, patients with very localized
disease, patients not undergoing treatment or noncurative treat-
ment and patients with no caregiver. In some cases, the difference
between compared groups was almost 9 points (e.g., scores of
32.87 for patients undergoing treatment vs. 45.29 for patients
not undergoing any kind of treatment), which represents a dif-
ference of almost 19% on a scale ranging from 12 to 60. These
results are consistent with the ﬁndings established in previous
studies [27,28].
One limitation of our study is that only a limited number of
focus groups were used for the item generation phase. Neverthe-
less, we did not believe it was necessary to include a larger
number because the concept to be measured (cancer-related
fatigue) is a reasonably limited concept. The lack of patients with
intense fatigue in the item reduction sample might be a more
serious limitation. Nevertheless, we felt it was both impractical
and ethically dubious to include such patients given the task
required of them in the item reduction phase. Concerns related to
the potential quality of responses from fatigued patients answer-
ing a series of 75 double items were dealt with by varying the
order of item administration (as previously explained) and by
allowing patients to rest if necessary. Last, further studies should
evaluate psychometric properties such as test–retest reliability or
sensitivity to change, which were not able to be evaluated in the
present study because of cross-sectional design of the ﬁeld study
done.
Conclusions
We have constructed a questionnaire to assess the attitudes and
beliefs about cancer-related fatigue and its treatment in clinical
practice that is feasible, reliable and valid and whose character-
istics and content are likely to make it highly practicable for use
in clinical practice in different Spanish-speaking cultures and
target populations. Nevertheless, before the questionnaire can be
used in clinical practice or in clinical or epidemiological research,
additional psychometric properties must be tested. A validated
study of the questionnaire is currently underway.
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Table 3 Factor analysis for the 12 retained items for the perform
questionnaire (N = 238)
Item loading for
the only factor
found with an
Eigen value >1
Physical limitations
The slightest effort makes me very tired. 0.759
My tiredness (due to my illness or its treatment) has
been very different to “normal” tiredness.
0.491
I’ve been tired the whole day long. 0.794
I’ve spent the whole day sitting down because of my
tiredness.
0.736
Activities of daily living
When I was tired, I’ve had to interrupt what I was
doing and rest to be able to continue.
0.806
I’ve been very slow performing my usual activities. 0.785
I’ve needed help with tasks around the house
because of my tiredness.
0.779
I’ve felt bad about feeling tired at work. 0.779
Beliefs and attitudes
In general, I believe my tiredness has made my life
worse.
0.669
I’ve felt that I’m going downhill because of my
tiredness.
0.583
I feel my tiredness has prevented me from living a
normal life.
0.773
I’ve stopped doing things I liked doing because
of my tiredness.
0.767
R2, % 53.7
Table 4 Score distributions, ﬂoor/ceiling effects, missing data, interscale correlations and internal consistency of the 12 retained items of the perform
questionnaire (N = 238)
Overall PL ADL BA
Items (n) 12 4 4 4
Mean 37.05 11.76 13.20 11.95
SD 9.23 3.36 4.02 3.49
Theoretical range* 12–60 4–20 4–20 4–20
Observed range 14–55 5–20 4–20 4–19
Floor† (%) 0 0 1.7 1.7
Ceiling‡ (%) 0 0.4 3.4 0
Completion rate§ (%) 77.3 94.5 93.7 85.3
Missing answers per item 1–27 2–11 2–27 1–9
CA 0.92 0.78 0.85 0.81
Interscale correlation range 0.81 (BA) to 0.91 (ADL) 0.52 (BA) to 0.68 (ADL) 0.58 (BA) to 0.68 (PL) 0.52 (PL) to 0.58 (ADL)
*Overall score range from 12 (greatest impact) to 60 (no impact). Dimension score range from 4 (greatest impact) to 20 (no impact).
†Percentage of patients with the worst possible score.
‡Percentage of patients with the best possible score.
§Percentage of respondents with no missing data in any of the 12 items.
ADL, activities of daily living; BA, beliefs and attitudes; PL, physical limitations; SD, standard deviation.
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